FDA warned Dr. Thomas Balshi/Intilight that its hydroquinone skin-lightening cream is an unapproved and misbranded new drug.
What happened
FDA reviewed the product label and the websites intilight.com and southflderm.com/product/intilight/, where INTILIGHT INTIMATE LIGHTENING TREATMENT is offered for sale. The letter says the product is intended as a skin bleaching drug and contains 2% hydroquinone. FDA concluded it is an unapproved new drug and misbranded because no approved application is in effect and it does not comply with section 505G for nonprescription drugs.
What FDA found
The product is an unapproved new drug because no FDA-approved application is in effect for it.
section 505(a) of the FD&C Act, 21 U.S.C. 355(a)The product is misbranded because it is a nonprescription drug that does not comply with section 505G and has no approved application.
section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)FDA says skin bleaching drug products, including hydroquinone products, were proposed as not generally recognized as safe and effective, so this product is deemed a new drug.
section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4); 71 FR 51146The label and website claims show the product is intended to lighten and whiten skin, making it a drug.
section 201(g)(1)(B) and (C) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), (C); 21 CFR 201.128Introducing the unapproved drug into interstate commerce is prohibited.
section 301(d) of the FD&C Act, 21 U.S.C. 331(d)Introducing the misbranded drug into interstate commerce is prohibited.
section 301(a) of the FD&C Act, 21 U.S.C. 331(a)
What FDA wants
FDA asks the company to respond in writing within 15 working days describing what it has done to correct the violations and prevent recurrence. If it cannot complete corrections in that time, it must state the reasons for delay and a schedule for completion.
Who should pay attention
- companies selling skin-lightening or bleaching creams
- retailers and websites offering hydroquinone products
- brands or contract manufacturers using hydroquinone in OTC drugs
This is a summary. Read the original letter on fda.gov.